(Reuters) – Pfizer Inc (PFE.N) has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV (MYL.O), a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.
The move, which brings blockbuster treatments Viagra and Lipitor under one umbrella with Mylan’s EpiPen, is part of a years-long effort by Pfizer to split into three parts – innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare. Pfizer agreed in December to combine its consumer health business with GlaxoSmithKline Plc’s. (GSK.L)
The combined company, which will get a new name, is expected to have 2020 revenue of $19 billion to $20 billion, with free cash flow expected to be more than $4 billion.
The pharmaceutical industry has been under intensifying pressure from lawmakers, including President Donald Trump, to keep prices down for U.S. consumers, which has limited profits and led to recent deals, such as Bristol-Myers Squibb Co’s (BMY.N) plan to buy Celgene Corp (CELG.O) and AbbVie Inc’s (ABBV.N) acquisition of Allergan Plc (AGN.N).
The new company, to be based in the United States and incorporated in Delaware, will be led by Michael Goettler, president of Pfizer’s Upjohn unit, which sells Pfizer’s older drugs that have lost patent protection.
Upjohn will issue $12 billion of debt at or before the separation, with proceeds going to Pfizer. Pfizer said it plans to use that cash to pay down its own debt.
Mylan said Chief Executive Heather Bresch, who took the helm in 2012 and faced intense political pressure over the high price of EpiPen, will retire after the deal closes. Mylan Chairman Robert Coury will become executive chairman of the new company.
“We think it is clear Mylan needed to do something to change direction,” Wells Fargo analyst David Maris said, adding that the deal is also recognition that Pfizer wanted out of generics.
A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 29, 2019. REUTERS/Brendan McDermid
Pfizer’s older drugs business has a much higher operating margin than Mylan’s, Maris added.
Mylan, which had a market value of $9.5 billion prior to Monday’s announcement, last year said it would review its business as it grapples with lower prices of generic drugs and declining sales of its EpiPen emergency allergy treatment.
In 2015, Mylan fended off a takeover attempt from rival Teva Pharmaceutical Industries (TEVA.TA) that would have valued the company at around $40 billion. Based on Monday’s share price, the company is worth around $11 billion. EpiPen sales fell sharply after Mylan was heavily criticized for steep price hikes on its device that delivers a life-saving shot epinephrine to treat severe allergic reactions. Bresch was called to testify before Congress in 2016, as the controversy put Mylan at the center of the ongoing U.S. debate over the high cost of prescription medicines.
Mylan’s shares have lost about a third of their value in 2019 through Friday’s close. The stock was up more than 12.9% at $20.84 on Monday, while Pfizer slipped 2% to $42.23.
JULY 29, 2019